Development and Characterization of Spray-Dried Combined Levofloxacin–Ambroxol Dry Powder Inhaler Formulation DOI Creative Commons

Ruwani K. Suraweera,

Kirsten Spann,

Emad L. Izake

et al.

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(12), P. 1506 - 1506

Published: Nov. 22, 2024

Background: This study explores the development and characterization of spray-dried composite microparticles consisting levofloxacin (LVX, a broad-spectrum antibiotic), ambroxol (AMB, mucolytic agent that has antibacterial antibiofilm properties), for intended application drug against lower respiratory tract infections (LRTIs). Methods: A range LVX to AMB mass ratios (1:1, 1:0.5, 1:0.25) were prepared, with without use dispersibility enhancer leucine (LEU), following pre-optimized parameters achieve required particle size (1–5 µm) flow properties. The formulations characterized by attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectroscopy, scanning electron microscopy (SEM), powder X-ray diffraction (PXRD), thermogravimetric analysis (TGA). in vitro aerosolization performance new formulation was evaluated twin-stage impinger (TSI) at rate 60 ± 5 L/min. Using validated RP-HPLC method, quantitatively determined. Results: combined LVX, AMB, LEU particles spherically shaped sizes ranging from 1.9 2.9 µm, thus complying requirements effective deep lung deposition. produced high yield enhanced properties characteristics formulations. showed remarkable impact on properties, 1:1 ratio demonstrating best FPFs both drugs. There must be balanced these components spray drying obtain appropriate property. addition 5% significantly (p < 0.005) improved FPF all formulations, probably enhancing surface hydrophobicity particles. Conclusions: antibiotics strong potential efficient delivery management LRTIs.

Language: Английский

Optimization, In Vitro, and In Silico Characterization of Theophylline Inhalable Powder Using Raffinose-Amino Acid Combination as Fine Co-Spray-Dried Carriers DOI Creative Commons

Petra Party,

Lomass Soliman, Attila Nagy

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(4), P. 466 - 466

Published: April 3, 2025

Background/Objectives: Dry powder inhalation is an attractive research area for development. Therefore, this work aimed to develop inhalable co-spray-dried theophylline (TN) microparticles, utilizing raffinose-amino acid fine carriers intended asthma therapy. The study addressed enhancing TN’s physicochemical and aerodynamic properties ensure efficient lung deposition. Methods: process involves spray-drying each formulation’s solution using a mini spray drier. A rigorous assessment was conducted on particle size distribution, structural thermal analysis, morphology study, in vitro silico investigation, counter addition the solubility, dissolution, diffusion of TN. Results: containing leucine glycine revealed superior characteristics (mass median diameter (MMAD): 4.6–5 µm, fraction (FPF): 30.6–35.1%, amorphous spherical structure) as candidates further development TN-DPIs, while arginine excluded due intensive aggregation hygroscopicity, which led poor performance. TN samples demonstrated micronized particles (D [0.5]: 3.99–5.96 µm) with predominantly structure (crystallinity index: 24.1–45.2%) significant solubility enhancement (~19-fold). Formulations leucine-glycine highest FPF (45.7–47.8%) deposition (39.3–40.1%), rapid drug release (~100% within 10 min), improved (2.29–2.43-fold), respectively. Moreover, confirmed microparticles (mean number = 2.3–2.02 µm). Conclusions: This innovative formulation possesses enhanced physicochemical, morphological, low-dose local treatment could be applied promising carrier dry inhaler

Language: Английский

Citations

1
Comprehensive In Vitro and In Silico Aerodynamic Analysis of High-Dose Ibuprofen- and Mannitol-Containing Dry Powder Inhalers for the Treatment of Cystic Fibrosis DOI Creative Commons

Petra Party,

Zsófia Ilona Piszman,

Árpád Farkas

et al.

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(11), P. 1465 - 1465

Published: Nov. 17, 2024

Cystic fibrosis is a hereditary disease, which causes the accumulation of dense mucus in lungs accompanied by frequent local inflammation. The non-steroidal anti-inflammatory drug ibuprofen (IBU) and mucolytic mannitol (MAN) can treat these symptoms. Compared to per os administration, lower dose drugs sufficient achieve desired effect delivering them pulmonary manner. However, it still challenge administer high doses lungs. We aim develop two inhaled powder formulations, single-drug product MAN combined formulation containing IBU MAN.

Language: Английский

Citations

4
Particulate platform for pulmonary drug delivery: Recent advances of formulation and fabricating strategies DOI
Zhibin Zhang, Mengya Jin, Xinyu Yang

et al.

International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown, P. 125601 - 125601

Published: April 1, 2025

Language: Английский

Citations

0
Enhanced pulmonary delivery of spray-dried theophylline: investigation of the trehalose and amino acid combinations as innovative fine carriers DOI Creative Commons
Lomass Soliman,

Petra Party,

Attila Nagy

et al.

European Journal of Pharmaceutical Sciences, Journal Year: 2025, Volume and Issue: unknown, P. 107109 - 107109

Published: April 1, 2025

Language: Английский

Citations

0
Development and Characterization of Spray-Dried Combined Levofloxacin–Ambroxol Dry Powder Inhaler Formulation DOI Creative Commons

Ruwani K. Suraweera,

Kirsten Spann,

Emad L. Izake

et al.

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(12), P. 1506 - 1506

Published: Nov. 22, 2024

Background: This study explores the development and characterization of spray-dried composite microparticles consisting levofloxacin (LVX, a broad-spectrum antibiotic), ambroxol (AMB, mucolytic agent that has antibacterial antibiofilm properties), for intended application drug against lower respiratory tract infections (LRTIs). Methods: A range LVX to AMB mass ratios (1:1, 1:0.5, 1:0.25) were prepared, with without use dispersibility enhancer leucine (LEU), following pre-optimized parameters achieve required particle size (1–5 µm) flow properties. The formulations characterized by attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectroscopy, scanning electron microscopy (SEM), powder X-ray diffraction (PXRD), thermogravimetric analysis (TGA). in vitro aerosolization performance new formulation was evaluated twin-stage impinger (TSI) at rate 60 ± 5 L/min. Using validated RP-HPLC method, quantitatively determined. Results: combined LVX, AMB, LEU particles spherically shaped sizes ranging from 1.9 2.9 µm, thus complying requirements effective deep lung deposition. produced high yield enhanced properties characteristics formulations. showed remarkable impact on properties, 1:1 ratio demonstrating best FPFs both drugs. There must be balanced these components spray drying obtain appropriate property. addition 5% significantly (p < 0.005) improved FPF all formulations, probably enhancing surface hydrophobicity particles. Conclusions: antibiotics strong potential efficient delivery management LRTIs.

Language: Английский

Citations

1